Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor...
PRESS RELEASE RESS RELEASE Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at...
LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of...
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been...
$2.5 Million in Annualized Revenues, 25% Projected Adjusted EBITDA Margin Post Integration, and Adds Over 3,700 Active Patients Quipt Has...
- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy...
UV1 vaccine combined with ipilimumab induced immune responses in 91% of melanoma patientsImmune responses persist and are detectable up to...
Lund, November 9, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today a presentation on naptumomab...
Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumorsBUFFALO, N.Y.,...
Press ReleaseStockholm, Sweden, November 9, 2021Immunicum to Present New Research Data at The Society for Immunotherapy of Cancer (SITC) Annual...
Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine®...
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to...
WINNIPEG, Manitoba, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a...
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery...
Company to host conference call and webcast on Friday, November 12, 2021 at 8:30 a.m. ETCAMBRIDGE, Mass., Nov. 09, 2021...
-Webinar to be held Friday, November 19, 2021 at 11:00 a.m. ET- -Featuring Harriet Kluger, M.D., renowned researcher, medical oncologist...
- License Enables Development of RNADD’s AntiSense Molecular Diagnostic Platform for Home-Use Infectious Disease Testing - BALTIMORE, Nov. 09, 2021 (GLOBE NEWSWIRE)...
Jefferies London Healthcare Conference 2021Evercore ISI 4th Annual HealthCONx Conference 202163th American Society of Hematology 2021 Congress (ASH-2021)MADRID, Spain and...
The Merkel cell trial will be prioritized over the previously planned Phase 2 trial in patients with intimal sarcoma, and...
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing...
